Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation

Status: Terminated
Location: See all (5) locations...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to learn about Smith-Lemli-Opitz Syndrome (SLOS). SLOS is an inherited condition that is caused by the body not making an enzyme as it should. The body needs the enzyme to help make cholesterol. SLOS can cause many health problems including slow growth and development, eating disorders, sleep disorders, behavior disorders, and eye diseases. Severe SLOS leads to birth defects and mental retardation and in many cases early death. The investigators plan to measure cholesterol and other sterol levels, perform clinical observations, whole body testing and imaging (brain MRIs), to learn more about the disease and its progression, differences in the clinical features among individuals with SLOS, and look at the effect of cholesterol supplementation in this condition. The study is an interventional study to characterize disease progression and correlations between clinical, biochemical and physiological features of the disease. The main hypothesis is that dietary cholesterol supplementation does not improve features of SLOS related to the brain (e.g. IQ, behavior).

Eligibility
Participation Requirements
Sex: All
Maximum Age: 85
Healthy Volunteers: f
View:

• Confirmed diagnosis of Smith-Lemli-Opitz Syndrome (SLOS)

• Males and females of all ages

• Willing and able to travel to OHSU or another STAIR site

Locations
United States
Maryland
Pdgen, Nichd, Nih, Dhhs
Bethesda
Nebraska
University of Nebraska Medical Center
Omaha
Ohio
Cincinnati Children'S Hospital Medical Center
Cincinnati
Oregon
Oregon Health and Science University
Portland
Pennsylvania
Children'S Hospital of Pittsburgh of Upmc
Pittsburgh
Time Frame
Start Date: 2011-01
Completion Date: 2015-12
Participants
Target number of participants: 21
Treatments
Experimental: Cholesterol supplementation
All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
Sponsors
Leads: Oregon Health and Science University

This content was sourced from clinicaltrials.gov